Caribou Biosciences Inc (NASDAQ:CRBU) has a beta value of 2.25 and has seen 1.32 million shares traded in the last trading session. The CRBU stock price is -312.38% off its 52-week high price of $8.33 and 25.74% above the 52-week low of $1.50. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.52 million shares traded. The 3-month trading volume is 1.18 million shares.
The consensus among analysts is that Caribou Biosciences Inc (CRBU) is Buy stock at the moment, with a recommendation rating of 1.44. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.4.
Caribou Biosciences Inc (NASDAQ:CRBU) trade information
Over the past 30 days, the shares of Caribou Biosciences Inc (NASDAQ:CRBU) have changed 14.12%. Short interest in the company has seen 9.94 million shares shorted with days to cover at 11.03.
Wall Street analysts have a consensus price target for the stock at $3, which means that the shares’ value could jump 32.67% from current levels. The projected low price target is $3.0 while the price target rests at a high of $3.0. In that case, then, we find that the current price level is -48.51% off the targeted high while a plunge would see the stock gain -48.51% from current levels.
Caribou Biosciences Inc (CRBU) estimates and forecasts
Figures show that Caribou Biosciences Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -32.44% over the past 6 months, with this year growth rate of -18.84%, compared to 18.00% for the industry. Revenue growth from the last financial year stood is estimated to be -73.80%.
8 analysts offering their estimates for the company have set an average revenue estimate of 2.02M for the current quarter. 2 have an estimated revenue figure of 2.75M for the next ending quarter. Year-ago sales stood 3.56M and 2.43M respectively for this quarter and the next, and analysts expect sales will shrink by -43.14% for the current quarter and -73.80% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -37.16% over the past 5 years. Earnings growth for 2024 is a modest -20.17% while over the next 5 years, the company’s earnings are expected to increase by 14.50%.
CRBU Dividends
Caribou Biosciences Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Caribou Biosciences Inc (NASDAQ:CRBU)’s Major holders
Insiders own 10.01% of the company shares, while shares held by institutions stand at 62.57% with a share float percentage of 69.53%. Investors are also buoyed by the number of investors in a company, with Caribou Biosciences Inc having a total of 182.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 6.95 million shares worth more than $11.39 million. As of 2024-06-30, BLACKROCK INC. held 7.7801% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 4.54 million shares as of 2024-06-30. The firm’s total holdings are worth over $7.45 million and represent 5.0891% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . As of Jun 30, 2024 , the former fund manager holds about 3.06% shares in the company for having 2.77 shares of worth $5.59 million while later fund manager owns 2.2 shares of worth $4.45 million as of Sep 30, 2024 , which makes it owner of about 2.43% of company’s outstanding stock.
